Is the Fixed Periodic Treatment Effective for the Tumor System without Complete Information?
Jiali Wang,1,2 Yixuan Zhang,1,2 Xiaoquan Liu,1,2 Haochen Liu1,2 1School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, People’s Republic of China; 2Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, People’s Republic of ChinaCorresponden...
Saved in:
Main Authors: | Wang J, Zhang Y, Liu X, Liu H |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/8d0e87111a09445f9834725a0e68eb9c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimizing Adaptive Therapy Based on the Reachability to Tumor Resistant Subpopulation
by: Jiali Wang, et al.
Published: (2021) -
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
by: Yu D, et al.
Published: (2021) -
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
by: Klempner SJ, et al.
Published: (2017) -
Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
by: Sergey V. Goryaynov
Published: (2021) -
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
by: Zhu VW, et al.
Published: (2019)